Clinical benefits and safety of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two glucose-containing dialysates a day in incident CAPD patients

Comparison of benefits and safety between a CAPD technique with one icodextrin containing and two glucose containing dialysate a day and a CAPD technique with four exchanges of glucose-containing dialysates: a multicentre, prospective, randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN23727549

Enrollment

Registered

2011-06-21

Start date

2008-04-14

Completion date

Unknown

Last updated

2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease/ continuous ambulatory peritoneal dialysis (CAPD) Nutritional, Metabolic, Endocrine End stage renal disease

Interventions

1. After enrollment, patients used four exchanges of glucose-containing dialysates a day 2. After one month, patients were randomly assigned to one of the two groups 3. Control group (GLU) used four

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: End-stage renal disease patients starting continuous ambulatory peritoneal dialysis (CAPD)

Exclusion criteria

Exclusion criteria: 1. Bedridden status 2. Dependency on tube feeding 3. Advanced liver cirrhosis 4. Current malignancy

Design outcomes

Primary

Measure	Time frame
1. Residual renal function (24h urine volume and renal creatinine clearance) at baseline, 6 months and 12 months 2. Ultrafiltration volume at baseline, 6 months and 12 months 3. Peritoneal glucose absorption at baseline, 6 months and 12 months 4. Peritoneal effluent CA125 levels at baseline, 6 months and 12 months	—

Secondary

Measure	Time frame
1. Dialysis adequacy (weekly Kt/Vurea and normalized protein equivalent of nitrogen appearance) at baseline, 6 months and 12 months 2. Use of anti-lipid drugs at baseline, 6 months and 12 months 3. Insulin requirements at baseline, 6 months and 12 months 4. Cardiothoracic index on chest radiographs at baseline, 6 months and 12 months 5. Body weight at baseline, 6 months and 12 months 6. Events of peritonitis during 12 months 7. Events of cardiovascular disease during 12 months	—

Measure

Time frame

1. Dialysis adequacy (weekly Kt/Vurea and normalized protein equivalent of nitrogen appearance) at baseline, 6 months and 12 months 2. Use of anti-lipid drugs at baseline, 6 months and 12 months 3. Insulin requirements at baseline, 6 months and 12 months 4. Cardiothoracic index on chest radiographs at baseline, 6 months and 12 months 5. Body weight at baseline, 6 months and 12 months 6. Events of peritonitis during 12 months 7. Events of cardiovascular disease during 12 months

—

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026